Peak Bio, Inc. (PKBO)
OTCMKTS: PKBO · Delayed Price · USD
0.0085
0.00 (0.00%)
Apr 29, 2024, 1:01 PM EDT - Market closed
Peak Bio Revenue
Peak Bio had revenue of $621.54K in the twelve months ending June 30, 2023, with 6.93% growth year-over-year. In the year 2022, Peak Bio had annual revenue of $607.68K with 15.02% growth.
Revenue (ttm)
$621.54K
Revenue Growth
+6.93%
P/S Ratio
0.31
Revenue / Employee
$29,597
Employees
21
Market Cap
190.37K USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 607.68K | 79.37K | 15.02% |
Dec 31, 2021 | 528.31K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionPKBO News
- 2 months ago - Shareholder Alert: Ademi LLP investigates whether Peak Bio Inc. has obtained a Fair Price in its transaction with Akari - PRNewsWire
- 2 months ago - Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit - GlobeNewsWire
- 4 months ago - Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing - GlobeNewsWire
- 8 months ago - Peak Bio, Inc. Announces Filing of Provisional Patent Applications for PH-1, a Novel and Specific Immunomodulatory ADC payload platform targeting RNA splicing - GlobeNewsWire
- 8 months ago - Peak Bio, Inc. Announces Up-listing to OTCQB Market - GlobeNewsWire
- 8 months ago - Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors - GlobeNewsWire
- 9 months ago - Peak Bio, Inc. Announces Amendment and Continued Access to Equity Line of up to $100 Million USD via an Accelerated Common Stock Purchase Transaction with White Lion Capital - GlobeNewsWire
- 9 months ago - Peak Bio, Inc. Presents Preclinical Data Highlighting Potential of Differentiated Trop2 PH1 (Novel Payload) ADC in Poster at 2023 AACR Annual Meeting - GlobeNewsWire